The Diagnosis and Management of Cardiovascular Disease in Cancer Patients

Current Problems in Cardiology

Volumn 33, Issue 4, 2008, Pages 163-196

  Yusuf, Syed Wamique ^a   Razeghi, Peter ^a   Yeh, Edward T H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE; ARSENIC TRIOXIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; BRAIN NATRIURETIC PEPTIDE; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; IMATINIB; INTERLEUKIN 2; IRINOTECAN; MITOMYCIN; MITOMYCIN C; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; THALIDOMIDE; TRASTUZUMAB;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADD ON THERAPY; ADVERSE OUTCOME; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD PRESSURE; BRADYCARDIA; BREAST CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER THERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; DEFIBRILLATION; DIASTOLIC HEART FAILURE; DRUG MEGADOSE; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FOLLOW UP; HEART BLOCK; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOTENSION; PATIENT MONITORING; PRACTICE GUIDELINE; QT PROLONGATION; T CELL LEUKEMIA; THROMBOEMBOLISM; TORSADE DES POINTES; VASCULAR DISEASE;

ACUTE CORONARY SYNDROME; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOOD PRESSURE; BRADYCARDIA; CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; COMORBIDITY; ENZYME INHIBITORS; HEART DISEASES; HEART FAILURE; HUMANS; MYOCARDIAL ISCHEMIA; NEOPLASMS; RISK FACTORS; THROMBOEMBOLISM; THROMBOSIS; TORSADES DE POINTES; VENOUS THROMBOSIS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 39749192587     PISSN: 01462806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2008.01.002     Document Type: Article

References (172)

1. Hoyert D.L., Heron M.P., Murphy S.L., et al. Deaths: final data for 2003. Natl Vital Stat Rep 54 (2006) 1-120
2. Mathers C.D., and Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3 (2006) e442
3. Ewer M.S., and Lippman S.M. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23 (2005) 2900-2902
4. Kerkela R., Grazette L., Yacobi R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12 (2006) 908-916
5. Ewer M.S., Ali M.K., Mackay B., et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol 2 (1984) 112-117
6. Ewer M.S., Vooletich M.T., Durand J.B., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23 (2005) 7820-7826
7. van Royen N., Jaffe C.C., Krumholz H.M., et al. Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol 77 (1996) 843-850
8. Tjeerdsma G., Meinardi M.T., van Der Graaf W.T., et al. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart 81 (1999) 419-423
9. Morandi P., Ruffini P.A., Benvenuto G.M., et al. Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m(2)) cyclophosphamide. Bone Marrow Transplant 28 (2001) 277-282
10. Morrison L.K., Harrison A., Krishnaswamy P., et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 39 (2002) 202-209
11. Suzuki T., Hayashi D., Yamazaki T., et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 136 (1998) 362-363
12. Okumura H., Iuchi K., Yoshida T., et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 104 (2000) 158-163
13. Nousiainen T., Vanninen E., Jantunen E., et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 251 (2002) 228-234
14. Urbanova D., Urban L., Carter A., et al. Cardiac troponins-biochemical markers of cardiac toxicity after cytostatic therapy. Neoplasma 53 (2006) 183-190
15. Cardinale D., Sandri M.T., Colombo A., et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109 (2004) 2749-2754
16. Cardinale D., Sandri M.T., Martinoni A., et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36 (2000) 517-522
17. Burjonroppa S.C.T.A., Xiao L.C., Johnson M.M., et al. Cancer patients with markedly elevated B-type Natriuretic peptide may not have volume overload. Am J Clini Oncol 30 (2007) 287-293
18. Yeh E.T. Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med 57 (2006) 485-498
19. Yeh E.T., Tong A.T., Lenihan D.J., et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109 (2004) 3122-3131
20. Von Hoff D.D., Layard M.W., Basa P., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91 (1979) 710-717
21. Wouters K.A., Kremer L.C., Miller T.L., et al. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131 (2005) 561-578
22. Slamon D., and Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28 (2001) 13-19
23. Shan K., Lincoff A.M., and Young J.B. Anthracycline-induced cardiotoxicity. Ann Intern Med 125 (1996) 47-58
24. Friedman M.A., Bozdech M.J., Billingham M.E., et al. Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. JAMA 240 (1978) 1603-1606
25. Jones R.L., Swanton C., and Ewer M.S. Anthracycline cardiotoxicity. Exp Opin Drug Saf 5 (2006) 791-809
26. Felker G.M., Thompson R.E., Hare J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342 (2000) 1077-1084
27. Kalay N., Basar E., Ozdogru I., et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48 (2006) 2258-2262
28. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
29. Bristol-Myers Squibb Company: Sprycel (Dasatinib) prescribing information. Princeton, NJ, 2006.
30. Valabrega G., Montemurro F., and Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol (2007) Jan 17 (Epub ahead print)
31. Sparano J.A. Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin Oncol 28 (2001) 20-27
32. Ewer M.S., Perez E.A., Baselga J., et al. Cardiac Safety Guidelines for the adjuvant use of trastuzumab (Herceptin) in HER-2 positive breast cancer. St.Gallen Primary Therapy of Early Breast Cancer (2007), 10th International Conference, St. Gallen, Switzlerland 14-17 March
33. Dow E., Schulman H., and Agura E. Cyclophosphamide cardiac injury mimicking acute myocardial infarction. Bone Marrow Transplant 12 (1993) 169-172
34. Biganzoli L., and Piccart M.J. The bigger the better?. or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer. Ann Oncol 8 (1997) 1177-1182
35. Nieto Y., Cagnoni P.J., Bearman S.I., et al. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. Biol Blood Marrow Transplant 6 (2000) 198-203
36. Quezado Z.M., Wilson W.H., Cunnion R.E., et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 118 (1993) 31-36
37. Klastersky J. Side effects of ifosfamide. Oncology 65 suppl 2 (2003) 7-10
38. Kandylis K., Vassilomanolakis M., Tsoussis S., et al. Ifosfamide cardiotoxicity in humans. Cancer Chemother Pharmacol 24 (1989) 395-396
39. Schimmel K.J., Richel D.J., van den Brink R.B., et al. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 30 (2004) 181-191
40. Meinardi M.T., Gietema J.A., van der Graaf W.T., et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18 (2000) 1725-1732
41. Togna G.I., Togna A.R., Franconi M., et al. Cisplatin triggers platelet activation. Thromb Res 99 (2000) 503-509
42. Verweij J., Funke-Kupper A.J., Teule G.J., et al. A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C. Med Oncol Tumor Pharmacother 5 (1988) 159-163
43. Shao Y., Pardini L., and Pardini R.S. Enhancement of the antineoplastic effect of mitomycin C by dietary fat. Cancer Res 54 (1994) 6452-6457
44. Gradishar W.J., and Vokes E.E. 5-Fluorouracil cardiotoxicity: a critical review. Ann Oncol 1 (1990) 409-414
45. Kuropkat C., Griem K., Clark J., et al. Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report. Am J Clin Oncol 22 (1999) 466-470
46. Schober C., Papageorgiou E., Harstrick A., et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 72 (1993) 2242-2247
47. Gianni L., Kearns C.M., Giani A., et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13 (1995) 180-190
48. Seidman A.D., Reichman B.S., Crown J.P., et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13 (1995) 1152-1159
49. Dombernowsky P., Gehl J., Boesgaard M., et al. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol 23 (1996) 23-27
50. Markman M., Kennedy A., Webster K., et al. Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors. J Clin Oncol 16 (1998) 3483-3485
51. Dillman R.O. Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. Cancer Invest 19 (2001) 833-841
52. Oshima K., Sakata-Yanagimoto M., Asano-Mori Y., et al. Cardiac complications after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab. Bone Marrow Transplant 36 (2005) 821-824
53. Lenihan D.J., Alencar A.J., Yang D., et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 104 (2004) 655-658
54. Basquiera A.L., Berretta A.R., Garcia J.J., et al. Coronary ischemia related to alemtuzumab therapy. Ann Oncol 15 (2004) 539-540
55. Shih T., and Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28 (2006) 1779-1802
56. D'Adamo D.R., Anderson S.E., Albritton K., et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 23 (2005) 7135-7142
57. Cohen M.C., Huberman M.S., and Nesto R.W. Recombinant alpha 2 interferon-related cardiomyopathy. Am J Med 85 (1988) 549-551
58. Sonnenblick M., Rosenmann D., and Rosin A. Reversible cardiomyopathy induced by interferon. BMJ 300 (1990) 1174-1175
59. Deyton L.R., Walker R.E., Kovacs J.A., et al. Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma. N Engl J Med 321 (1989) 1246-1249
60. Zimmerman S., Adkins D., Graham M., et al. Irreversible, severe congestive cardiomyopathy occurring in association with interferon alpha therapy. Cancer Biother 9 (1994) 291-299
61. Jensen B.V., Skovsgaard T., and Nielsen S.L. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 13 (2002) 699-709
62. Tallaj J.A., Franco V., Rayburn B.K., et al. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant 24 (2005) 2196-2201
63. Giesler G., Lenihan D., Tong A., et al. Withdrawal of ace-inhibitors and beta blockers in cancer patients with congestive heart failure leads to severe adverse cardiovascular effects. Circulation 109 suppl 4 (2003) 665
64. Iliescu C., Yusuf S.W., Swafford J., et al. Impact of angiotensin converting enzyme inhibitors and carvedilol on recovery of cardiac function in Imatinib (gleevac) associated cardiomyopathy. J Card Fail 11 suppl (2005) 54
65. Shaik N., Yusuf S.W., Swafford J., et al. The role of Valsartan and Carvedilol in patients with chemotherapy associated cardiomyopathy who are intolerant to angiotensin converting enzyme inhibitors. J Card Fail Suppl 11 (2005) 87
66. Woods M.L., Yusuf S.W., Swafford J., et al. Milrinone and Carvedilol in medical management of chemotherapy induced acute decompensated class 1V heart failure. J Cardiac Fail 8 suppl (2002) 296
67. Steinherz L.J., Graham T., Hurwitz R., et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 89 (1992) 942-949
68. Ganame J., Claus P., Eyskens B., et al. Acute cardiac functional and morphological changes after Anthracycline infusions in children. Am J Cardiol 99 (2007) 974-977
69. Zeidman A., Dicker D., and Mittelman M. Interferon-induced vasospasm in chronic myeloid leukaemia. Acta Haematol 100 (1998) 94-96
70. Lu J.I., Carhart R.L., Graziano S.L., et al. Acute coronary syndrome secondary to fluorouracil infusion. J Clin Oncol 24 (2006) 2959-2960
71. Frickhofen N., Beck F.J., Jung B., et al. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 13 (2002) 797-801
72. Cardinale D., Colombo A., and Colombo N. Acute coronary syndrome induced by oral capecitabine. Can J Cardiol 22 (2006) 251-253
73. Schrader C., Keussen C., Bewig B., et al. Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma. Eur J Med Res 10 (2005) 498-501
74. Stefenelli T., Kuzmits R., Ulrich W., et al. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J 9 (1988) 552-556
75. Clarke M., Collins R., Darby S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 (2005) 2087-2106
76. Rutqvist L.E., and Johansson H. Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer 61 (1990) 866-868
77. Paszat L.F., Mackillop W.J., Groome P.A., et al. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries. J Clin Oncol 16 (1998) 2625-2631
78. Giordano S.H., Kuo Y.F., Freeman J.L., et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 97 (2005) 419-424
79. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavorable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 355 (2000) 1757-1770
80. Harris J.R., and Hellman S. Put the "hockey stick" on ice. Int J Radiat Oncol Biol Phys 15 (1988) 497-499
81. Vallis K.A., Pintilie M., Chong N., et al. Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer. J Clin Oncol 20 (2002) 1036-1042
82. Hancock S.L., Tucker M.A., and Hoppe R.T. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 270 (1993) 1949-1955
83. Basavaraju S.R., and Easterly C.E. Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. Med Phys 29 (2002) 2391-2403
84. Jurado J., and Thompson P.D. Prevention of coronary artery disease in cancer patients. Pediatr Blood Cancer 44 (2005) 620-624
85. Stewart J.R., and Fajardo L.F. Radiation-induced heart disease: an update. Prog Cardiovasc Dis 27 (1984) 173-194
86. Veinot J.P., and Edwards W.D. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol 27 (1996) 766-773
87. Brosius III F.C., Waller B.F., and Roberts W.C. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med 70 (1981) 519-530
88. McEniery P.T., Dorosti K., Schiavone W.A., et al. Clinical and angiographic features of coronary artery disease after chest irradiation. Am J Cardiol 60 (1987) 1020-1024
89. Stewart J.R., Fajardo L.F., Gillette S.M., et al. Radiation injury to the heart. Int J Radiat Oncol Biol Phys 31 (1995) 1205-1211
90. Theodoulou M., and Seidman A.D. Cardiac effects of adjuvant therapy for early breast cancer. Semin Oncol 30 (2003) 730-739
91. Tribble D.L., Barcellos-Hoff M.H., Chu B.M., et al. Ionizing radiation accelerates aortic lesion formation in fat-fed mice via SOD-inhibitable processes. Arterioscler Thromb Vasc Biol 19 (1999) 1387-1392
92. Sarkiss M.G., Yusuf S.W., Warneke C.L., et al. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer 109 (2007) 621-627
93. Orzan F., Brusca A., Conte M.R., et al. Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br Heart J 69 (1993) 496-500
94. Katz N.M., Hall A.W., and Cerqueira M.D. Radiation induced valvulitis with late leaflet rupture. Heart 86 (2001) E20
95. Rituxan package insert (2001), IDEC Pharmaceuticals, San Diego, CA
96. Cersosimo R.J. Monoclonal antibodies in the treatment of cancer. Part 1. Am J Health Syst Pharm 60 (2003) 1531-1548
97. Herceptin package insert (2001), Genentech, San Francisco
98. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
99. Hedrick E., Kozloff M., Hainsworth J., et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results froma large observational registry in the US (BRiTE). J Clin Oncol 24 suppl (2006) 155s (abstract 3536)
100. Trousseau A. Phlegmasia Alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris (1865), The New Sydenham Society, London 94-99
101. Khorana A.A. Malignancy, thrombosis and Trousseau: the case for an eponym. J Thromb Haemost 1 (2003) 2463-2465
102. Luzzatto G., and Schafer A.I. The prethrombotic state in cancer. Semin Oncol 17 (1990) 147-159
103. Levine M.N., Gent M., Hirsh J., et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 318 (1988) 404-407
104. Goodnough L.T., Saito H., Manni A., et al. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 54 (1984) 1264-1268
105. Levine M., Hirsh J., Gent M., et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343 (1994) 886-889
106. Nordstrom M., Lindblad B., Anderson H., et al. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ 308 (1994) 891-894
107. Lip G.Y., Chin B.S., and Blann A.D. Cancer and the prothrombotic state. Lancet Oncol 3 (2002) 27-34
108. Heit J.A., Silverstein M.D., Mohr D.N., et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160 (2000) 809-815
109. Khorana A.A., Francis C.W., Culakova E., et al. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104 (2005) 2822-2829
110. Bennett C.L., Angelotta C., Yarnold P.R., et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 296 (2006) 2558-2560
111. Zangari M., Anaissie E., Barlogie B., et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98 (2001) 1614-1615
112. Urbauer E., Kaufmann H., Nosslinger T., et al. Thromboembolic events during treatment with thalidomide. Blood 99 (2002) 4247-4248
113. Barlogie B., Tricot G., Anaissie E., et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354 (2006) 1021-1030
114. Shah M.A., Ilson D., and Kelsen D.P. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 23 (2005) 2574-2576
115. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
116. Chen H.X., Mooney M., Boron M., et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 24 (2006) 3354-3360
117. Kilickap S., Abali H., and Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 21 (2003) 3542-3543
118. Sevelda P., Mayerhofer K., Obermair A., et al. Thrombosis with paclitaxel. Lancet 343 (1994) 727
119. Weijl N.I., Rutten M.F., Zwinderman A.H., et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 18 (2000) 2169-2178
120. Nuver J., Smit A.J., van der Meer J., et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 23 (2005) 9130-9137
121. Behrendt C.E., and Ruiz R.B. Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy. Thromb Haemost 90 (2003) 734-737
122. Recio F.O., Piver M.S., Hempling R.E., et al. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 78 (1996) 2157-2163
123. Licciardello J.T., Moake J.L., Rudy C.K., et al. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 42 (1985) 296-300
124. Pretnar-Oblak J., Zaletel M., Jagodic M., et al. Thrombosis of internal carotid artery after cisplatin-based chemotherapy. Eur Neurol 57 (2007) 109-110
125. Kearon C., Julian J.A., Newman T.E., et al. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med 128 (1998) 663-677 Erratum in: Ann Intern Med 1998;129:425
126. Bates S.M., and Ginsberg J.S. Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med 351 (2004) 268-277
127. Torbicki A., Van Beek E.J.R., Charbonnier B., et al. Task Force on Pulmonary Embolism. European Society of Cardiology Guidelines on diagnosis and management of acute pulmonary embolism. Eur Heart J 21 (2000) 1301-1336
128. Yusuf S.W., Woods M., and Swafford J. Medical image. Pulmonary grume. NZ Med J 119 (2006) U2126
129. Kaplan B.M., Miller A.J., Bharati S., et al. Complete AV block following mediastinal radiation therapy: electrocardiographic and pathologic correlation and review of the world literature. J Interv Card Electrophysiol 1 (1997) 175-188
130. Dubrey S.W., Cha K., Anderson J., et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 91 (1998) 141-157
131. Takenaka S., Mitsudo K., Inoue K., et al. Successful treatment of primary cardiac lymphoma with atrioventricular nodal block. Int Heart J 46 (2005) 927-931
132. Okmen E., Erdinler I., Oguz E., et al. An unusual cause of reflex cardiovascular syncope: vagal paraganglioma. Ann Noninvasive Electrocardiol 8 (2003) 173-176
133. Owen P.J., Lazarus J.H., and Morse R.E. Unusual complications of thyroid carcinoma. Postgrad Med J 79 (2003) 55-56
134. Altundag O., Celik I., and Kars A. Recurrent asymptomatic bradycardia episodes after cisplatin infusion. Ann Pharmacother 35 (2001) 641-642
135. Miya T., Fujikawa R., Fukushima J., et al. Bradycardia induced by irinotecan: a case report. Jpn J Clin Oncol 28 (1998) 709-711
136. McGuire W.P., Rowinsky E.K., Rosenshein N.B., et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111 (1989) 273-279
137. Lai K.H., Tsai Y.T., Lee S.D., et al. Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection. Cancer Chemother Pharmacol 23 (1989) 54-56
138. Dilger J.A., Rho E.H., Que F.G., et al. Octreotide-induced bradycardia and heart block during surgical resection of a carcinoid tumor. Anesth Analg 98 (2004) 318-320 table of contents
139. Hinterseer M., Becker A., Kaab S., et al. Thalidomide-induced symptomatic third-degree atrioventricular block. Clin Res Cardiol 95 (2006) 474-476
140. Perez-Verdia A., Angulo F., Hardwicke F.L., et al. Acute cardiac toxicity associated with high-dose intravenous methotrexate therapy: case report and review of the literature. Pharmacotherapy 25 (2005) 1271-1276
141. Huang C.H., Chen W.J., Wu C.C., et al. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient. Pacing Clin Electrophysiol 22 (1999) 965-967
142. Ferlitsch A., Kreil A., Bauer E., et al. Bradycardia and sinus arrest during percutaneous ethanol injection therapy for hepatocellular carcinoma. Eur J Clin Invest 34 (2004) 218-223
143. Kilickap S., Akgul E., Aksoy S., et al. Doxorubicin-induced second degree and complete atrioventricular block. Europace 7 (2005) 227-230
144. Franchin G., Vaccher E., Gobitti C., et al. Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma. Oral Oncol 41 (2005) 526-533
145. Satoh K., Sakamoto N., Shinohe Y., et al. Indigo carmine-induced bradycardia in a patient during general anesthesia. Anesth Analg 92 (2001) 276-277
146. Keefe D.L. The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?. Oncologist 7 (2002) 65-72
147. Schurmeyer T.H., Engeroff B., Dralle H., et al. Cardiological effects of catecholamine-secreting tumours. Eur J Clin Invest 27 (1997) 189-195
148. Paschalis-Purtak K., Pucilowska B., Prejbisz A., et al. Cardiac arrests, atrioventricular block, and pheochromocytoma. Am J Hypertens 17 (2004) 544-545
149. Engelen M.A., Juergens K.U., Breithardt G., et al. Interatrial conduction delay and atrioventricular block due to primary cardiac lymphoma. J Cardiovasc Electrophysiol 169 (2005) 26
150. Gregoratos G., Abrams J., Epstein A.E., et al. ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J Am Coll Cardiol 40 (2002) 1703-1719
151. Viskin S. Long QT syndromes and torsade de pointes. Lancet 354 (1999) 1625-1633
152. Dessertenne F. Ventricular tachycardia with two variable opposing foci. Arch Mal Coeur Vaiss 59 (1966) 263-272
153. Kay G.N., Plumb V.J., Arciniegas J.G., et al. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol 2 (1983) 806-817
154. Walker G., Wilcock A., Carey A.M., et al. Prolongation of the QT interval in palliative care patients. J Pain Symptom Manage 26 (2003) 855-859
155. Soignet S.L. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist 6 suppl 2 (2001) 11-16
156. www.torsades.org accessed on May 4, 2007
157. Ferrari S., Figus E., Cagnano R., et al. The role of corrected QT interval in the cardiologic follow-up of young patients treated with Adriamycin. J Chemother 8 (1996) 232-236
158. Oztop I., Gencer M., Okan T., et al. Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level. QT interval and dispersion in patients with gastrointestinal system cancers. Jpn J Clin Oncol 34 (2004) 262-268
159. Cooney M.M., Radivoyevitch T., Dowlati A., et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 10 (2004) 96-100
160. Saliba W., Erdogan O., and Niebauer M. Polymorphic ventricular tachycardia in a woman taking cesium chloride. Pacing Clin Electrophysiol 24 (2001) 515-517
161. Gowda R.M., Khan I.A., Wilbur S.L., et al. Torsade de pointes: the clinical considerations. Int J Cardiol 96 (2004) 1-6
162. Committee for Propierary Medicinal Products. Points to consider; The assessment of the potential for QT interval prolongation by non cardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products. London 17th. http://www.eudra.org/emea.html accessed on May 4 2007
163. Priori S.G., Schwartz P.J., Napolitano C., et al. Risk stratification in the long-QT syndrome. N Engl J Med 348 (2003) 1866-1874
164. Roden D.M. Drug-induced prolongation of the QT interval. N Engl J Med 350 (2004) 1013-1022
165. Zeltser D., Justo D., and Halkin IV A. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore) 82 (2003) 282-290
166. Murray K.T. Ibutilide. Circulation 97 (1998) 493-497
167. Abernethy D.R., and Flockhart D.A. Molecular basis of cardiovascular drug metabolism: implications for predicting clinically important drug interactions. Circulation 101 (2000) 1749-1753
168. TRISENOX. www.fda.gov
169. Tzivoni D., Banai S., Schuger C., et al. Treatment of torsade de pointes with magnesium sulfate. Circulation 77 (1988) 392-397
170. Assimes T.L., and Malcolm I. Torsade de pointes with sotalol overdose treated successfully with lidocaine. Can J Cardiol 14 (1998) 753-756
171. Vukmir R.B., and Stein K.L. Torsades de pointes therapy with phenytoin. Ann Emerg Med 20 (1991) 198-200
172. Kocheril A.G., Bokhari S.A., and Batsford IV W.P. Long QTc and torsades de pointes in human immunodeficiency virus disease. Pacing Clin Electrophysiol 20 (1997) 2810-2816